Sex: F
Vaccine: RAB, UNK
Symptoms: Inappropriate schedule of product administration, Interchange of vaccine products, No adverse event
Clinical narrative: In Thailand the patient received three doses of the vaccine with the name Speeda, and will receive the fourth dose with Rabavert; RabAvert vaccine had to be given early; Case reference number US-BN-2022-001383, is a spontaneous case report initially received on 24-Jun-2022 from a nurse (reference number: USBAV22-0410) and concerns a female patient of unknown age. . The patient's medical history and concomitant medication details were not provided.  On an unspecified dates, the patient received the first three doses of co-suspect Speeda vaccine (Rabies vaccine inact (vero)) for post-exposure rabies immunisation due to a bite (unspecified) in Thailand, at an unknown dose, route or site of administration.  On an unspecified date, the patient was vaccinated with RabAvert ((Inactivated, Strain Flury LEP); batch number unknown) as a fourth dose for post-exposure rabies immunization due to a bite, at an unknown dose, route or anatomical location of administration (explicitly coded as 'Interchange of vaccine products'). It was stated that the RabAvert vaccine had to be given early (explicitly coded as 'inappropriate schedule of vaccine administered').  It was not reported whether the patient experience any adverse reaction after vaccination.  Additional information received on 27-Jun-2022 included local case ID.; Reporter's Comments: A female patient of unknown age was vaccinated with RabAvert as a fourth dose for post-exposure rabies immunization due to a bite, after the patient received the first three doses of co-suspect Speeda vaccine, which is considered as interchange of vaccine products. It was stated that the RabAvert vaccine had to be given earlier, which is considered as inappropriate schedule of product administration. No associated adverse events have been reported with the reported medication error. Interchange of vaccine products and inappropriate schedule of product administration are considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Interchange of vaccine products and inappropriate schedule of product administration have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age was vaccinated with RabAvert as a fourth dose for post-exposure rabies immunization due to a bite, after the patient received the first three doses of co-suspect Speeda vaccine, which is considered as interchange of vaccine products. It was stated that the RabAvert vaccine had to be given earlier, which is considered as inappropriate schedule of product administration. No associated adverse events have been reported with the reported medication error. Interchange of vaccine products and inappropriate schedule of product administration are considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Interchange of vaccine products and inappropriate schedule of product administration have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.